Shattuck Labs, Inc. (STTK) Operating Margin
- Operating margin · 12 months: Value -5578.60%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -5578.60% | Operating income / revenue. Period ending 2026-06-30. $-55.79M ÷ $1.00M × 100 ≈ -5578.60% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -55.79M USD | Operating Income (Loss) |
| Revenue | 1.00M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 39.32M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-55.79M | $1.00M | (m) | $39.32M | (m) | -5578.60% |
| 2026-03-31 | $-52.66M | $1.00M | (m) | $36.30M | (m) | -5266.40% |
| 2025-12-31 | $-51.51M | $1.00M | (m) | $35.27M | (m) | -5150.80% |
| 2025-09-30 | $-57.78M | $1.00M | (m) | $41.61M | (m) | -5777.80% |
| 2025-06-30 | $-64.98M | $3.00M | (m) | $50.31M | (m) | -2168.23% |
| 2025-03-31 | $-74.91M | $4.61M | (m) | $60.87M | (m) | -1626.40% |
| 2024-12-31 | $-80.57M | $5.72M | (m) | $67.21M | (m) | -1408.27% |
| 2024-09-30 | $-79.88M | $6.43M | (m) | $67.04M | (m) | -1241.29% |
| 2024-06-30 | $-90.56M | $4.12M | (m) | $74.94M | (m) | -2195.81% |
| 2024-03-31 | $-90.34M | $2.71M | (m) | $73.91M | (m) | -3327.44% |
| 2023-12-31 | $-91.96M | $1.66M | (m) | $74.31M | (m) | -5549.61% |
| 2023-09-30 | $-99.28M | $1.33M | (m) | $80.97M | (m) | -7448.01% |
| 2023-06-30 | $-95.91M | $859.00K | (m) | $75.62M | (m) | -11165.66% |
| 2023-03-31 | $-100.82M | $709.00K | (m) | $80.38M | (m) | -14220.59% |
| 2022-12-31 | $-103.33M | $652.00K | (m) | $82.90M | (m) | -15848.01% |
| 2022-09-30 | $-67.81M | $30.34M | (m) | $77.22M | (m) | -223.49% |
| 2022-06-30 | $-60.16M | $32.03M | (m) | $73.49M | (m) | -187.83% |
| 2022-03-31 | $-57.01M | $27.75M | (m) | $65.41M | (m) | -205.47% |
| 2021-12-31 | $-45.27M | $30.02M | (m) | $56.56M | (m) | -150.81% |
| 2021-09-30 | $-66.53M | $1.28M | (m) | $50.14M | (m) | -5193.29% |
| 2021-06-30 | $-60.78M | $1.82M | (m) | $46.81M | (m) | -3347.19% |
| 2021-03-31 | $-42.59M | $9.23M | (m) | $39.68M | (m) | -461.56% |
| 2020-12-31 | $-36.93M | $9.93M | (m) | $37.48M | (m) | -371.76% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-25.07M | $9.89M | (m) | $29.22M | (m) | -253.53% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |